Enliven Therapeutics, Inc. — fact timeline

Enliven Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. valued at approximately $376.0 million (effective 2026-06-11).

“On June 11, 2026, Enliven Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 8,933,334 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $37.50 per share (the “Firm Shares”), and, in lieu of Firm Shares to certain investors, pre-funded warrants to purchase 1,733,333 Shares (the “Pre-Funded Warrants”) at a price to the public of $37.499 per Pre-Funded Warrant, which represents the per share public offering price for the Firm Shares less the $0.001 exercise price for each such Pre-Funded Warrant.”

Enliven Therapeutics, Inc.: Increased authorized shares of common stock from 100,000,000 to 200,000,000 (effective 2026-06-09).

“On June 9, 2026, following stockholder approval, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000, which amendment was effective as of the date of filing.”

Enliven Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $23.6 million.

“Enliven reported a net loss of $23.6 million for the first quarter of 2026”

Enliven Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $22.7 million.

“Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update”

Lori Kunkel was appointed as Class III Director at Enliven Therapeutics, Inc..

“On April 8, 2024, the Board of Directors (the “Board”) of Enliven Therapeutics, Inc. (the “Company”) appointed Lori Kunkel, MD to serve as a Class III director, with a term expiring at the Company’s 2026 annual meeting of stockholders.”

Enliven Therapeutics, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $90 million (effective 2024-03-19).

“On March 19, 2024, Enliven Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 5,357,144 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at $14.00 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants") to purchase 1,071,505 shares of Common Stock”

Enliven Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss of $19.4 million for the fourth quarter of 2023.

“Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today reported financial results for the fourth quarter and full year ended December 31, 2023”

Enliven Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $20.8 million.

“Enliven reported a net loss of $20.8 million for the third quarter of 2023”

Enliven Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $16.7 million.

“Enliven reported a net loss of $16.7 million for the second quarter of 2023, compared to a net loss of $8.9 million for the second quarter of 2022.”

Enliven Therapeutics, Inc. terminated Controlled Equity Offering SM Sales Agreement (the "Prior Sales Agreement") with Cantor Fitzgerald & Co. (effective 2023-06-23).

“On June 23, 2023, the Company delivered written notice to Cantor Fitzgerald to terminate the Prior Sales Agreement pursuant to Section 12(b) thereof, effective as of June 23, 2023.”

Enliven Therapeutics, Inc. entered into Open Market Sale Agreement SM (the "Sales Agreement") with Jefferies LLC valued at up to $200.0 million (effective 2023-06-23).

“On June 23, 2023, Enliven Therapeutics, Inc. (the "Company") entered into an Open Market Sale Agreement SM (the "Sales Agreement") with Jefferies LLC as the Company's sales agent (the "Agent"), pursuant to which the Company may offer and sell shares (the "Shares") of its common stock, par value $0.001 per share ("Common Stock") from time to time through the Agent, in such share amounts as the Company may specify by notice to the Agent, in accordance with the terms and conditions set forth in the Sales Agreement.”

Enliven Therapeutics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-23 meeting.

“For Against Abstain 32,543,338 1,460 165”

Enliven Therapeutics, Inc. shareholders approved Election of two Class III Directors at the 2023-06-23 meeting.

“Name of Director For Withheld Broker Non-Votes Richard Heyman, Ph.D. 30,518,067 385,508 1,641,388 Samuel Kintz, M.B.A. 30,900,278 3,297 1,641,388”

Enliven Therapeutics, Inc.: Adopted a new Code of Business Conduct and Ethics, superseding the pre-Merger code (effective 2023-02-23).

“In connection with the Merger, the Board adopted a new Code of Business Conduct and Ethics (the “ Code of Conduct ”) on February 23, 2023.”

Enliven Therapeutics, Inc.: Filed Stock Split Amendment to effect reverse stock split and common stock reduction, and filed Name Change Amendment to change company name to Enliven Therapeutics, Inc (effective 2023-02-23).

“On February 23, 2023, the Company filed the Stock Split Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split effective as of 5:00 p.m. on February 23, 2023.”

Enliven Therapeutics, Inc. underwent a change of control involving Former Enliven (formerly Enliven Therapeutics, Inc.) (closed 2023-02-23).

“On February 23, 2023, the Company completed its business combination with Former Enliven in accordance with the terms of the Agreement and Plan of Merger, dated as of October 13, 2022”

Enliven Therapeutics, Inc. engaged Deloitte & Touche LLP as its auditor.

“On February 23, 2023, following the completion of the Merger, the Audit Committee approved the appointment of Deloitte as the Company’s independent registered public accounting firm, effective immediately.”

Enliven Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.

“On February 23, 2023, following the completion of the Merger, EY was informed that the Audit Committee of the Board (the “ Audit Committee ”) approved EY’s dismissal as the Company’s independent registered public accounting firm, effective immediately.”

Michael P. Gray resigned as Chief Financial Officer and Chief Operating Officer at Enliven Therapeutics, Inc..

“On February 23, 2023, immediately prior to and effective upon the closing of the Merger, Rahul D. Ballal, Ph.D., resigned from his position as the Company’s President and Chief Executive Officer, and Michael P. Gray resigned from his position as the Company’s Chief Financial Officer and Chief Operating Officer.”

Rahul D. Ballal, Ph.D. resigned as President and Chief Executive Officer at Enliven Therapeutics, Inc..

“On February 23, 2023, immediately prior to and effective upon the closing of the Merger, Rahul D. Ballal, Ph.D., resigned from his position as the Company’s President and Chief Executive Officer, and Michael P. Gray resigned from his position as the Company’s Chief Financial Officer and Chief Operating Officer.”

Laura Williams, M.D., MPH resigned as Director at Enliven Therapeutics, Inc..

“David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”

Barbara J. Dalton, Ph.D resigned as Director at Enliven Therapeutics, Inc..

“David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”

Carl Goldfischer, M.D. resigned as Director at Enliven Therapeutics, Inc..

“David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”

Edward Conner, M.D. resigned as Director at Enliven Therapeutics, Inc..

“David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”

Mark Chin resigned as Director at Enliven Therapeutics, Inc..

“David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”

David Bonita, M.D. resigned as Director at Enliven Therapeutics, Inc..

“David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”

David M. Mott resigned as Director at Enliven Therapeutics, Inc..

“David M. Mott, David Bonita, M.D., Mark Chin, Edward Conner, M.D., Carl Goldfischer, M.D., Barbara J. Dalton, Ph.D, and Laura Williams, M.D., MPH, resigned from the Board and committees of the Board on which they respectively served, which resignations were not the result of any disagreements with the Company relating to the Company’s operations, policies or practices.”

Enliven Therapeutics, Inc. shareholders approved To approve an amendment to the 2020 ESPP to increase the number of shares of common stock reserved for issuance under the 2020 ESPP to 1,628,535 shares..

“Proposal No. 5. To approve an amendment to the 2020 ESPP to increase the number of shares of common stock reserved for issuance under the 2020 ESPP to 1,628,535 shares. This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain Broker Non-Votes 20,492,019 952,287 16,911 1,214,365”

Enliven Therapeutics, Inc. shareholders approved To approve the adoption of the AR 2020 Plan..

“Proposal No. 4. To approve the adoption of the AR 2020 Plan. This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain Broker Non-Votes 20,405,072 1,049,082 7,063 1,214,365”

Enliven Therapeutics, Inc. shareholders approved To adopt and approve an amendment to the restated certificate of incorporation of Imara to effect a reverse stock split of Imara common stock, by a ratio of not less than 1-for-3 and not more than 1-for-7, or any whole number in between, and a proportionate reduction in the number of authorized shar.

“Proposal No. 3. To adopt and approve an amendment to the restated certificate of incorporation of Imara to effect a reverse stock split of Imara common stock, by a ratio of not less than 1-for-3 and not more than 1-for-7, or any whole number in between, and a proportionate reduction in the number of authorized shares of Imara common stock, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of Imara’s board of directors. This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain 22,464,937 193,805 16,840”

Enliven Therapeutics, Inc. shareholders approved To adopt and approve an amendment to the restated certificate of incorporation of Imara to increase the number of authorized shares of Imara common stock from 200,000,000 shares to 400,000,000 shares..

“Proposal No. 2. To adopt and approve an amendment to the restated certificate of incorporation of Imara to increase the number of authorized shares of Imara common stock from 200,000,000 shares to 400,000,000 shares. This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain 22,389,433 268,310 17,839”

Enliven Therapeutics, Inc. shareholders approved To approve the issuance of shares of common stock of Imara pursuant to the terms of the Merger Agreement for purposes of Nasdaq Listing Rules 5635(a), (b) and (d)..

“Proposal No. 1. To approve the issuance of shares of common stock of Imara pursuant to the terms of the Merger Agreement for purposes of Nasdaq Listing Rules 5635(a), (b) and (d). This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain Broker Non-Votes 21,428,092 29,419 3,706 1,214,365”

Enliven Therapeutics, Inc. shareholders approved Approval of the sale of assets related to the PDE9 program to Cardurion at the 2022-11-09 meeting.

“Proposal No. 1: To approve the sale by the Company to Cardurion of tovinontrine (IMR-687) and all other assets of the Company related to its PDE9 program, pursuant to the terms of the Asset Purchase Agreement, for an upfront cash payment of $34,750,000 upon closing of the Asset Sale (in addition to $250,000 previously paid by Cardurion to the Company upon execution of a non-binding term sheet), a $10,000,000 potential future payment that may become payable if Cardurion achieves a proof of concept milestone or other specified clinical milestones and a $50,000,000 potential future payment that may become payable if Cardurion achieves specified regulatory and/or commercial milestone events, in each case as described in the Asset Purchase Agreement and subject to the terms and conditions of the Asset Purchase Agreement (the “ Asset Sale Proposal ”). This proposal was approved by the requisite vote of the Company’s stockholders. For Against Abstain Broker Non-Votes 18,366,825 11,907 47,876”

Enliven Therapeutics, Inc. completed a disposition involving Cardurion Pharmaceuticals, Inc. for $34,750,000 upfront cash payment (closed 2022-11-10).

“On November 10, 2022, the Asset Sale was consummated and, in accordance with the Asset Purchase Agreement, Cardurion paid to Imara an upfront cash payment of $34,750,000 upon closing of the Asset Sale.”

Kenneth Attie departed as Chief Medical Officer at Enliven Therapeutics, Inc..

“Kenneth Attie, M.D., the Company’s Chief Medical Officer will separate from the Company effective April 20, 2022.”

Sara Nayeem resigned as director at Enliven Therapeutics, Inc..

“On October 21, 2021, Dr. Sara Nayeem announced that she will resign from the board of directors of IMARA Inc., effective November 15, 2021, due to a change in her employment.”